Nothing Special   »   [go: up one dir, main page]

MX2022002418A - Composiciones y metodos de tratamiento de enfermedades vasculares. - Google Patents

Composiciones y metodos de tratamiento de enfermedades vasculares.

Info

Publication number
MX2022002418A
MX2022002418A MX2022002418A MX2022002418A MX2022002418A MX 2022002418 A MX2022002418 A MX 2022002418A MX 2022002418 A MX2022002418 A MX 2022002418A MX 2022002418 A MX2022002418 A MX 2022002418A MX 2022002418 A MX2022002418 A MX 2022002418A
Authority
MX
Mexico
Prior art keywords
methods
compositions
vascular diseases
treating vascular
vpcs
Prior art date
Application number
MX2022002418A
Other languages
English (en)
Inventor
Robert Lanza
Maria Mirotsou
Nutan Prasain
Amrita Singh
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of MX2022002418A publication Critical patent/MX2022002418A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere en general a nuevas células progenitoras vasculares derivadas de mesodermo (meso-VPC) y métodos para producir meso-VPC. La presente invención también se refiere a métodos para tratar una enfermedad vascular, tal como la isquemia crítica de las extremidades, mediante la administración de las meso-VPC a un sujeto.
MX2022002418A 2019-08-28 2020-08-27 Composiciones y metodos de tratamiento de enfermedades vasculares. MX2022002418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962892724P 2019-08-28 2019-08-28
PCT/US2020/048076 WO2021041591A1 (en) 2019-08-28 2020-08-27 Compositions and methods of treating vascular diseases

Publications (1)

Publication Number Publication Date
MX2022002418A true MX2022002418A (es) 2022-03-22

Family

ID=72428364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002418A MX2022002418A (es) 2019-08-28 2020-08-27 Composiciones y metodos de tratamiento de enfermedades vasculares.

Country Status (12)

Country Link
US (1) US20220288131A1 (es)
EP (1) EP4022038A1 (es)
JP (1) JP2022545737A (es)
KR (1) KR20220049618A (es)
CN (1) CN115003794A (es)
AU (1) AU2020337444A1 (es)
BR (1) BR112022003659A2 (es)
CA (1) CA3151636A1 (es)
IL (1) IL290891A (es)
MX (1) MX2022002418A (es)
TW (1) TW202122573A (es)
WO (1) WO2021041591A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
CN114231481B (zh) * 2021-12-21 2023-07-18 中国人民解放军总医院 一种重编程真皮成纤维细胞为内皮祖细胞的化学诱导方法
WO2024020399A1 (en) * 2022-07-19 2024-01-25 Lung Biotechnology Pbc Methods for differentiating endothelial cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377923A1 (en) 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
KR101923290B1 (ko) 2008-05-06 2018-11-28 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포 및 비-생착성 혈관 세포
US8470596B2 (en) * 2008-06-30 2013-06-25 University College Cork, National University Of Ireland Primitive vascular progenitor cells and uses thereof
US20110305672A1 (en) * 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
US20140045265A1 (en) * 2011-02-16 2014-02-13 Salk Institute For Biological Studies Robust and efficient differentiation of human pluripotent stem cells to multipotent vascular progenitors
EP2718425B1 (en) * 2011-06-09 2017-05-10 F. Hoffmann-La Roche AG Method for differentiation of pluripotent stem cells into vascular bed cells
EP2778223B1 (en) * 2011-11-08 2016-11-23 National University Corporation Nagoya University Vascular progenitor cell sheet derived from induced pluripotent stem cells, and production method therefor
TW202344258A (zh) 2011-11-30 2023-11-16 安斯泰來再生醫藥協會 利用血管母細胞產生間葉基質細胞之方法
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
WO2015153586A1 (en) * 2014-03-31 2015-10-08 The Johns Hopkins University Pluripotent stem cell therapies for ischemic retinopathies
GB201408712D0 (en) * 2014-05-16 2014-07-02 Univ Leuven Kath Mesodermal progenitor cells
WO2016185457A1 (en) * 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
JP6646311B2 (ja) * 2015-07-17 2020-02-14 国立大学法人京都大学 多能性幹細胞から中胚葉前駆細胞および血液血管前駆細胞への分化誘導法
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
BR112019002584A2 (pt) * 2016-08-10 2019-05-21 Indiana University Research And Technology Corporation método para a geração de células do tipo células formadoras de colônia do mesoderma e/ou endoteliais apresentando capacidade de formação de vasos sanguíneos in vivo
US20200360563A1 (en) * 2018-01-30 2020-11-19 University Of Georgia Research Foundation, Inc. Methods for Vascular Construction and Products Therefrom

Also Published As

Publication number Publication date
KR20220049618A (ko) 2022-04-21
WO2021041591A1 (en) 2021-03-04
JP2022545737A (ja) 2022-10-28
EP4022038A1 (en) 2022-07-06
AU2020337444A1 (en) 2022-03-24
US20220288131A1 (en) 2022-09-15
CN115003794A (zh) 2022-09-02
TW202122573A (zh) 2021-06-16
IL290891A (en) 2022-04-01
BR112022003659A2 (pt) 2022-05-24
CA3151636A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
MX2021005047A (es) Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
TN2017000320A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
MX2019007088A (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
WO2022038365A3 (en) Fumarate derivatives and their medical use
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2022007671A (es) Compuestos antihelminticos que comprenden una estructura de azaindoles.
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2023006744A (es) Compuestos antihelminticos que comprenden una estructura de tienopiridina.
MX2021011576A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2022000203A (es) Composiciones de liberacion sostenida de endoxifeno.
WO2022246154A3 (en) Antibodies that bind to c1s and uses thereof
WO2019100052A3 (en) Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.